Founded in 2014 and headquartered in New York City, New York, Roivant Sciences Ltd. is a tech-enabled healthcare company... Read More. Beyond the Werewolf and Vaccitech offerings, more drug developers are slated to go public during the first week of May. Immunovant Appoints Pete Salzmann as Chief Executive Officer. Investor Relations Company Overview. as Chief Executive Officer. Roivant Sciences Ltd is located in HAMILTON, Pembroke, Bermuda and is part of the Investment Firms Industry. Roivant Sciences, Inc. is located in New York, NY, United States and is part of the Biotechnology Research Services Industry. Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Accomplishments in M&A transactions, Chapter 11 restructuring and developing Treasury and Investor Relations functions. He spent six years at Amgen working in product development, investor relations, and product licensing roles, which include the creation of the company’s corporate venture capital program. Investor Relations Contact . Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates. Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Contacts: Sarepta Therapeutics, Inc. Investors: Ian Estepan, 617-274-4052, iestepan@sarepta.com Media: Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com. Careers. NEW YORK and BASEL, Switzerland, June 5, 2019 /PRNewswire/ -- Immunovant, a biopharmaceutical company focused on developing innovative therapies for patients living with debilitating autoimmune diseases, today announced the appointment of Pete Salzmann, M.D. Investors Information and tools including share price information, dividends, and the latest reports, results and news. Trout is headquartered in New York and has additional offices in Waltham, Massachusetts and San Fr ancisco. Their forecasts range from $16.00 to $16.25. Roivant Sciences is funded by 7 investors. Transfer Agent. Pinterest is where people go to discover, dream and do. Sumitomo Dainippon Pharma is rebuilding its business foundation by pursuing core strategies laid out in the Mid-Term Business Plan 2022 which consists of the “establishment of a growth engine” and “building a flexible and efficient organization” in order to ensure sustained growth after expiration of U.S. market … Roivant Sciences Vivek Ramaswamy ... Ph.D., as SVP of regulatory affairs and Jonae Barnes as SVP of investor relations and corporate communications. Description. Urovant Sciences is a biopharmaceutical company advancing urologic patient care through development of innovative therapies and exceptional licensing opportunities. Contact Information Investors Bruce Cousins Executive Vice President and Chief Financial Officer Phone: 604-419-3200 Email: bcousins@arbutusbio.com. With over 15 years of HR experience, Ms. Kelton joins at an important time as Aruvant is … Immunovant, Inc is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Head of Investor Relations Email: a.fudukidis@affimed.com Tel. Roivant is an existing investor in San Francisco-headquartered Datavant, which provides data sharing services to the healthcare industry. Our Business; This is "Vivek Ramaswamy at Second Annual Roivant Pipeline Day" by Roivant Sciences on Vimeo, the home for high quality videos and the people who love them. Roivant will be responsible for clinical development and commercialization worldwide, and Affimed retains an option for co-promotion.“This partnership represents an important milestone as … : +1 (917) 436-8102. Roivant Sciences, which raised $1.1 billion in equity last summer from the SoftBank Vision … SAN DIEGO, May 11, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its subsidiary, Arena Pharmaceuticals GmbH, and Roivant Sciences Ltd., have entered into a Development, Marketing and Supply Agreement for nelotanserin, Arena's internally discovered inverse agonist of the 5-HT2A receptor.The agreement grants Roivant exclusive worldwide … +41 589 112 110. September 08, 2015. Find contact's direct phone number, email address, work history, and more. Tiffany Tolmie Manager, Investor Relations Phone: … A webcast will be archived on the Investor Relations page of the Urovant Sciences website immediately after the call and available for at least 30 days. Arbutus Investors Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: ttolmie@arbutusbio.com. View Matthew Blischak's business profile as Vice President, Intellectual Property & Counsel at Roivant Sciences. Investor Relations PR Newswire Roivant Provides Corporate Updates Provided by PR Newswire. ... Finance/CFO/Investor Relations… Statement of Limitations (1/2) This investor presentation (this “Presentation”) was prepared by Montes Archimedes Acquisition Corp. (“SPAC”) and Roivant Sciences Ltd. (the “Company”) in connection with the proposed transactions (the “Business Combination”) contemplated by the Business Combination Agreement, by and among SPAC, the Company and one of its affiliates. The R&D Day event will be webcast live on March 29, 2019 at 8:30am ET on the investor relations section of Axovant’s website at www.axovant.com. Prior to his role at Cowen Healthcare Investments, Dr. Pham was as a Senior Analyst on the investment team at Roivant Sciences, which is a biopharmaceutical company that acquires drugs in development and then establishes NewCos to continue their respective developments. We encourage investors and potential investors to consult our website regularly for important information about us. They browse their feeds for inspiration, search for topics they're interested in and click on Pins to learn more. Investor Relations | Urovant Sciences. '. +1 817 615 2789. investor.relations@alcon.com. Since its inception in 2014, Roivant has launched over 20 …. Operator of a healthcare company designed to reduce the time and cost of the drug development process. Ms. Clark-Schoeb will lead our internal and external communications efforts, investor relations, media effort and work with the rare disease and … LGD-6972 to be a foundational program for Metavant, a new company formed by Roivant to pursue the development of innovative therapies for cardiometabolic diseases. Dan Mannes Vice President of Investor Relations (862) 345-5456 ir@covanta.com. Leveraging our AI-based integrated computational platform, LANCE, we have identified seven novel clinical and preclinical candidates across various areas of unmet medical need. Roivant Pipeline Day will be held on Thursday, June 6, 2019 in New York City. (Employees and Sales figures are modelled). Roivant Sciences Ltd has 3 total employees across all of its locations and generates $467,565 in sales (USD). Beyond the Werewolf and Vaccitech offerings, more drug developers are slated to go public during the first week of May. Contact Information - Roivant. May 3, 2021 - 7:00 am. This press release features multimedia. SAN DIEGO--(BUSINESS WIRE) -- ... LHA Investor Relations Bruce Voss (310) 691-7100 bvoss@lhai.com. For more information, and to receive a copy of the early warning report filed in respect of the above matters, please visit www.roivant.com. Roivant … The Investor Relations website contains information about Myovant Sciences Ltd.'s business for stockholders, potential investors, and financial analysts. Jun 9, 2021 11:40 AM UTC. On average, they anticipate Urovant Sciences' share price to reach $16.17 in the next twelve months. From distribution to monitoring, our solutions keep your investors, employees, analysts and the media informed about your company. Roivant’s newest financing event: a $200 million raise at a post-money valuation of $7 billion, led by NovaQuest Capital Management, which is an investor in two of Roivant… Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: acutler@arbutusbio.com. Dr. Pham joined Cowen Healthcare Investments in November 2019 and focuses on investments into biotechnology companies. Roivant Sciences Paul Davis Head of Communications paul.davis@roivant.com +1 (646) 495-5310 Poxel SA Jonae R. Barnes Senior Vice President, Investor Relations and Public Relations … July 15, 2016. Headquarters: 151 W 42nd Street, 15th Floor, New York City, New York, 10036, United States. Biotech startup Roivant cuts staff, forms two new subsidiaries. Ms. Clark-Schoeb will lead our internal and external communications efforts, investor relations, media effort and work with the rare disease and sickle cell patient communities we are working so hard to serve.” With over 15 years of HR experience, Ms. Kelton joins at an important time as Aruvant is rapidly growing. “Alex brings extensive operational and regulatory experience in the life sciences industry that … Roivant Pipeline Day will be held on Thursday, June 6, 2019 in New York City. Do NOT follow this link! Dermavant Science Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutics in medical dermatology. We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. People on Pinterest are here to take action. Affimed entered into a licensing and strategic collaboration agreement with Roivant Sciences under which the Company will receive $60 million in upfront consideration, including $40 million in cash and pre-funded R&D and $20 million of Roivant equity, up to an additional $2 billion in future milestones and tiered royalties. Roivant’s investment will take the form of preferred shares which will be convertible into common shares at a conversion price of $7.13 per share (a 15% premium to the closing stock price on September 29, 2017). The deal with Roivant will enable sustainable drug discovery and generate cash flows that can be invested in Sumitomo Dainippon's strategic therapeutic areas of psychiatry, neurology, oncology and cell therapies, Sumitomo Dainippon CEO Hiroshi Nomura said in an investor presentation Sept. 6. SAN DIEGO--(BUSINESS WIRE) -- ... LHA Investor Relations Bruce Voss (310) 691-7100 bvoss@lhai.com. This suggests that the stock has a possible downside of 0.5%. On his 30th birthday last month, Vivek Ramaswamy had a lot to celebrate. Roivant Contact. From July 2018 to December 2019, Ms. Potter served as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences. Roivant Sciences Paul Davis Head of Communications paul.davis@roivant.com +1 (646) 495-5310 Poxel SA Jonae R. Barnes Senior Vice President, Investor Relations and Public Relations jonae.barnes@poxelpharma.com +1 617 818 2985 Investor relations / Media - EU/US Trophic Communications Stephanie May or Joanne Tudorica Wolf previously served at … The deal with Roivant will enable sustainable drug discovery and generate cash flows that can be invested in Sumitomo Dainippon's strategic therapeutic areas of psychiatry, neurology, oncology and cell therapies, Sumitomo Dainippon CEO Hiroshi Nomura said in an investor presentation Sept. 6. Sixth Street, Goldman invest in $7b merger of Datavant and Ciox Health. Investor relations; Talent; ... Roivant’s deal sets its market cap at $7.3bn. Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: ttolmie@arbutusbio.com. Since 1995, they have been providing companies in the sector with access to the U.S. institutional investment community. Paul Davis Email: paul.davis@roivant.com Tel. Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas. Their latest funding was raised on Nov 13, 2018 from a Private Equity round. Other. Companies built by Roivant have conducted eight consecutive positive Phase 3 studies with two FDA approvals to date. Public Relations Solutions . Investors Roivant Investor Relations ir@roivant.com. The event is scheduled to begin at 1:00 p.m. Visit this section Tiger Cub O. Andreas Halvorsen’s Greenwich, Connecticut-based Viking Global Investors said in a regulatory filing late Wednesday that it has made an investment in Roivant … Roivant Sciences has acquired Silicon Therapeutics on Feb 26, 2021. They acquired Silicon Therapeutics for $450M. Roivant Sciences has raised a total of $1.9B in funding over 4 rounds. Their latest funding was raised on Nov 13, 2018 from a Private Equity round. Roivant Sciences is funded by 7 investors. Novaquest Capital Management and QVT Financial are the most recent investors. Roivant Sciences has made 3 investments. Their most recent investment was on Oct 8, 2020, when Datavant raised $40M. Accomplishments in M&A transactions, Chapter 11 restructuring and developing Treasury and Investor Relations functions. An archived webcast will be available on Axovant’s website for 30 days following the event. Roivant's long-range mission is to reduce the time and cost of developing and delivering new medicines for patients. Investor Relations Solutions. ... Investor Relations. and for the formation of a Strategic Alliance with Roivant Sciences (Head Offices: London and Basel; Founder & CEO: Vivek Ramaswamy) as of December 27, 2019. Ms. Potter has served as a member of our board since September 2018. We see a world where the promise of our breakthrough biotechnologies is … Paul Davis Roivant … Novaquest Capital Management and QVT Financial are the most recent investors. Media Zach Kouwe / Doug Allen Dukas Linden Public Relations (646) 808-3665 zkouwe@dlpr.com; doug@dlpr.com. SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has been appointed general counsel. Boston, MA Research & Development At Roivant, we are passionate about discovering and developing new drugs to impact patients' lives. Aruvant Sciences, a part of the Roivant family of companies, is a clinical-stage biopharmaceutical company committed to developing and commercializing transformative gene therapies for rare diseases. Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: acutler@arbutusbio.com. Ms. Media Zach Kouwe / Doug Allen Dukas Linden Public Relations (646) 808-3665 zkouwe@dlpr.com; doug@dlpr.com. Investor Relations Corporate Profile. Axovant’s Vivek Ramaswamy Aims to Reinvent Dementia Treatment. share: Share on Facebook Tweet on Twitter Post to Reddit. Their forecasts range from $24.00 to $32.00. Roivant concurrently invested USD 15 million (approximately EUR 12 million) in Poxel through subscription in newly-issued ordinary shares at EUR 8.5 per share ... Investor relations / Media - … Pinterest Investor Relations. Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that it has completed the procedure related to stock transfers, etc. 5 brokerages have issued twelve-month price objectives for Myovant Sciences' shares. Roivant Sciences Overview Since its founding in 2014, Roivant has put over 40 medicines into development across a wide range of disease areas. LGD-6972 to be a foundational program for Metavant, a new company formed by Roivant to pursue the development of innovative therapies for cardiometabolic diseases. Source: Sarepta Therapeutics, Inc. Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. The Trout Group LLC is an investor relations and strategic advisory firm exclusively serving the life sciences industry. ... is a subsidiary of Roivant … Wolf previously served at … This suggests a possible upside of 36.0% from the stock's current price. Investors Roivant Investor Relations [email protected] Media Zach Kouwe / Doug Allen Dukas Linden Public Relations (646) 808-3665 [email protected]; [email protected] Paul Davis And in follow-on offerings, COMPASS Pathways raises $144m and Aldeyra brings in $125m. Paul Davis Roivant … Roivant is proud to support Arbutus in taking on this bold mission through an expanded relationship. Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates. There are 16 companies in the Roivant Sciences, … About Covanta. Roivant Sciences has made 3 … Investors Roivant Investor Relations ir@roivant.com. On average, they expect Myovant Sciences' share price to reach $28.40 in the next twelve months. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Integrated tools designed to help you tell your brand story and engage media, investors, employees and all of your key stakeholders. The R&D Day event will be webcast live on March 29, 2019 at 8:30am ET on the investor relations section of Axovant’s website at www.axovant.com. Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology. Contact Alcon Investor Relations. And in follow-on offerings, COMPASS Pathways raises $144m and Aldeyra brings in $125m. Roivant Sciences General Information Description. Public Company Edition: Roivant’s deal sets its market cap at $7.3bn. Ms. Clark-Schoeb will lead our internal and external communications efforts, investor relations, media effort and work with the rare disease and sickle cell patient communities we are working so hard to serve." ET and will continue until approximately 4:30 p.m. '. Campus Recruiting. ... Investor Relations Phone: 604 … American Stock Transfer & Trust Company, LLC 6201 15th Avenue Brooklyn, NY 11219 (800) 937-5449 / (718) 921-8124 (718) 236-2641 info@amstock.com Website. The event will feature presentations and Q&A sessions from executives across the Roivant family of companies highlighting new clinical data and investments in technology. ET. Tiago M Girao is Chief Financial Officer at Roivant Sciences Ltd. See Tiago M Girao's compensation, career history, education, & memberships. A link to investor presentation materials is included below. 3 brokerages have issued 12 month price objectives for Urovant Sciences' stock. For the fourth fiscal quarter ended March 31, 2017, research and development expenses were $40.8 million, of which $5.2 million was attributable to non-cash, share-based compensation expense.General and administrative expenses for the fourth quarter were $12.3 million, of which $3.4 million was attributable to non-cash, share-based compensation expense. Kaitlin Ugolik. Billionaire Andreas Halvorsen ’s Viking Global Investors disclosed on Wednesday that it has made an investment in Roivant Sciences, the private holding company that … More than 250 million people depend on Pinterest for new ideas, and they want to hear from you. There are 16 companies in the Roivant Sciences Ltd corporate family. Tarsus is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients with unmet needs. Roivant Sciences Vivek Ramaswamy ... Ph.D., as SVP of regulatory affairs and Jonae Barnes as SVP of investor relations and corporate communications. Media David Schull Russo Partners Phone: 858-717-2310 Email: david.schull@russopartnersllc.com. HONG KONG & BURLINGTON, Mass.--(BUSINESS WIRE)--Roivant Sciences GmbH and ArQule, Inc. (NASDAQ: ARQL) today announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater China.As part of the collaboration, ArQule has granted a Roivant subsidiary an exclusive license to develop and … Learn More . ... About Axovant Gene Therapies. Roivant Sciences today announced it has entered into a definitive agreement to acquire Silicon Therapeutics for $450 million in Roivant equity, with additional potential regulatory and commercial milestone payments. Since December 2019, Ms. Potter has served as the Chief Executive Officer of Sumitovant Biopharma. Enzyvant is an accelerator for transformative regenerative medicines with a focus on tissue-based therapies for rare conditions. Roivant’s drug discovery capabilities include the leading computational physics-based platform for in silico drug design and optimization as well as machine learning-based models for protein degradation. Media David Schull Russo Partners Phone: 858-717-2310 Email: david.schull@russopartnersllc.com Source: Arbutus Biopharma Corporation Roivant Sciences, Inc. has 120 total employees across all of its locations and generates $33.33 million in sales (USD). More Info. Urovant Sciences is advancing urologic patient care by delivering and developing innovative therapies. Roivant Sciences has raised a total of $1.9B in funding over 4 rounds. Associate Director / Director - Computational Modeling and Design. ... About Axovant Gene Therapies. Sign-up for news. ... (SVP), communications, leading our investor relations, public relations, advocacy relations and government affairs work. Genevant Sciences Roivant Provides Corporate Updates Roivant … Message. Investment firm Sixth Street, which has also made a significant new investment, will join the merged company’s board of directors at deal completion, Datavant and Ciox Health added. Aruvant Sciences, part of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on developing and commercializing gene therapies for the treatment of rare diseases. A former hedge fund investor, Ramaswamy founded Roivant with the idea of acquiring a portfolio of promising early-stage experimental therapies … An archived webcast will be available on Axovant’s website for 30 days following the event.